Patent · US Active

IL-21 variants

US8034326B2 · kind B2 · utility

14Cited by

12References

17Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Siv Annegrethe Hjorth · Avenue Madeleine, DK
Kent Bondensgaard · Frederikssund, DK
Dennis Madsen · Bunkeflostrand, SE

Key dates

Filing date	Apr 18, 2006
Grant date	Oct 11, 2011
Priority date	—
Expiry date	Jan 7, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.